Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials
Dimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos, Asterios Karagiannis
Topics & Concepts
MedicineRuxolitinibRandomized controlled trialJanus kinaseInternal medicineCytokine stormClinical endpointTofacitinibMechanical ventilationExtracorporeal membrane oxygenationTocilizumabOncologyCoronavirus disease 2019 (COVID-19)DiseaseCytokineInfectious disease (medical specialty)Bone marrowMyelofibrosisRheumatoid arthritisCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchInflammasome and immune disorders